开云app官网登录入口网页版-官方正版

#ixekizumab#

20篇内容 | 983人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1487588, encodeId=6397148e588c8, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=ARD：ixekizumab 在银屑病关节炎患者中的安全性：来自超过2000患者年暴露的四项临床试验的数据, objectType=article, longId=731154, objectId=1e2be3115479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e2be3115479, replyNumber=0, likeNumber=75, createdTime=2022-07-05, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e2be3115479, moduleTitle=ARD：ixekizumab 在银屑病关节炎患者中的安全性：来自超过2000患者年暴露的四项临床试验的数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1e2be3115479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487587, encodeId=c4bd148e587f6, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=JEADV:Suckinumab与Ixekizumab治疗脓疱型和红皮病型银屑病的临床比较, objectType=article, longId=301109, objectId=649330110913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649330110913, replyNumber=0, likeNumber=72, createdTime=2022-03-20, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649330110913, moduleTitle=JEADV:Suckinumab与Ixekizumab治疗脓疱型和红皮病型银屑病的临床比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=649330110913)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487586, encodeId=50fa148e58663, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性, objectType=article, longId=299288, objectId=c2b8299288cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2b8299288cb, replyNumber=0, likeNumber=77, createdTime=2022-02-22, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2b8299288cb, moduleTitle=J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c2b8299288cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487585, encodeId=61f3148e5851b, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=JEADV:Risankizumab和Ixekizumab治疗生殖器银屑病的比较, objectType=article, longId=292962, objectId=4e8d292962c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e8d292962c5, replyNumber=0, likeNumber=76, createdTime=2021-12-29, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e8d292962c5, moduleTitle=JEADV:Risankizumab和Ixekizumab治疗生殖器银屑病的比较, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4e8d292962c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487584, encodeId=02bb148e58494, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=Br J Dermatol：ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性, objectType=article, longId=292150, objectId=0b012921503e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b012921503e, replyNumber=0, likeNumber=82, createdTime=2021-12-19, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b012921503e, moduleTitle=Br J Dermatol：ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0b012921503e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487583, encodeId=e804148e5839f, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=JEADV:Ixekizumab可中到重度生殖器银屑病相关的性影响, objectType=article, longId=221429, objectId=2def221429fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2def221429fb, replyNumber=0, likeNumber=75, createdTime=2021-12-03, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2def221429fb, moduleTitle=JEADV:Ixekizumab可中到重度生殖器银屑病相关的性影响, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2def221429fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487582, encodeId=3d95148e58244, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性, objectType=article, longId=216821, objectId=a6d72168217e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6d72168217e, replyNumber=0, likeNumber=67, createdTime=2021-09-09, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6d72168217e, moduleTitle=ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a6d72168217e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487581, encodeId=b6d4148e5817c, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=JAAD:Ixekizumab 的长期疗效和安全性, objectType=article, longId=216744, objectId=ea16216e443b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea16216e443b, replyNumber=0, likeNumber=74, createdTime=2021-09-08, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea16216e443b, moduleTitle=JAAD:Ixekizumab 的长期疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ea16216e443b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487580, encodeId=74a0148e58064, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=如何治疗继发于阿达木单抗功效丧失的化脓性汗腺炎？可选择Ixekizumab, objectType=article, longId=203139, objectId=2ea820313948, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ea820313948, replyNumber=0, likeNumber=67, createdTime=2020-11-10, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ea820313948, moduleTitle=如何治疗继发于阿达木单抗功效丧失的化脓性汗腺炎？可选择Ixekizumab, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2ea820313948)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487579, encodeId=0a59148e57957, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=Lancet：Ixekizumab 治疗非放射学轴向脊椎关节炎, objectType=article, longId=184493, objectId=b1191844931b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1191844931b, replyNumber=0, likeNumber=116, createdTime=2019-12-11, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1191844931b, moduleTitle=Lancet：Ixekizumab 治疗非放射学轴向脊椎关节炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b1191844931b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487578, encodeId=fba3148e578b0, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）, objectType=article, longId=183366, objectId=0e97183366d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e97183366d9, replyNumber=0, likeNumber=42, createdTime=2019-11-23, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e97183366d9, moduleTitle=Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0e97183366d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487577, encodeId=65f3148e57728, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=2019年ACR / ARP：COAST-X研究展示了ixekizumab治疗非放射性轴性脊柱关节炎的积极数据, objectType=article, longId=182957, objectId=980118295e5b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=980118295e5b, replyNumber=0, likeNumber=60, createdTime=2019-11-15, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=980118295e5b, moduleTitle=2019年ACR / ARP：COAST-X研究展示了ixekizumab治疗非放射性轴性脊柱关节炎的积极数据, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=980118295e5b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487576, encodeId=e05f148e5768e, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=Arthritis Rheumatol：ixekizumab对放射性轴性脊柱关节炎的疗效和安全性, objectType=article, longId=151941, objectId=f6a61519418d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6a61519418d, replyNumber=0, likeNumber=58, createdTime=2018-10-28, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6a61519418d, moduleTitle=Arthritis Rheumatol：ixekizumab对放射性轴性脊柱关节炎的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f6a61519418d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487575, encodeId=f23b148e5750d, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=Lancet:IL-17A单抗ixekizumab可有效改善X线轴向骨关节炎患者症状, objectType=article, longId=151699, objectId=f88a1516999f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88a1516999f, replyNumber=0, likeNumber=73, createdTime=2018-10-25, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88a1516999f, moduleTitle=Lancet:IL-17A单抗ixekizumab可有效改善X线轴向骨关节炎患者症状, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f88a1516999f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487574, encodeId=85fc148e57466, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=Br J Dermatol：Ixekizumab治疗银屑病起效迅速且疗效较优, objectType=article, longId=118007, objectId=adce11800e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adce11800e5c, replyNumber=0, likeNumber=79, createdTime=2017-10-30, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adce11800e5c, moduleTitle=Br J Dermatol：Ixekizumab治疗银屑病起效迅速且疗效较优, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=adce11800e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487573, encodeId=d562148e5731f, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=NEJM：新药物ixekizumab可根治牛皮癣, objectType=article, longId=70721, objectId=ebeae0721d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebeae0721d1, replyNumber=0, likeNumber=96, createdTime=2016-06-15, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebeae0721d1, moduleTitle=NEJM：新药物ixekizumab可根治牛皮癣, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ebeae0721d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487572, encodeId=e6fb148e572a6, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=The Lancet：单抗药物ixekizumab中和白介素IL-17A 成功治疗银屑病, objectType=article, longId=52031, objectId=a0e8520314d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0e8520314d, replyNumber=0, likeNumber=61, createdTime=2015-06-14, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0e8520314d, moduleTitle=The Lancet：单抗药物ixekizumab中和白介素IL-17A 成功治疗银屑病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a0e8520314d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487571, encodeId=060a148e5711c, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=Lancet：治疗中度至重度银屑病，ixekizumab优于依那西普, objectType=article, longId=52002, objectId=b83e5200272, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b83e5200272, replyNumber=0, likeNumber=54, createdTime=2015-06-13, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b83e5200272, moduleTitle=Lancet：治疗中度至重度银屑病，ixekizumab优于依那西普, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b83e5200272)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487570, encodeId=ea8b148e570d1, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=礼来IL-17A单抗ixekizumab银屑病关节炎III期成功, objectType=article, longId=49722, objectId=d82a49e227a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d82a49e227a, replyNumber=0, likeNumber=62, createdTime=2015-04-24, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d82a49e227a, moduleTitle=礼来IL-17A单抗ixekizumab银屑病关节炎III期成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d82a49e227a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1487569, encodeId=8341148e569a1, content=<a href='/topic/show?id=ed671016333' target=_blank style='color:#2F92EE;'>#ixekizumab#</a>, objectTitle=礼来（Lilly）公司牛皮癣单抗药物ixekizumab中期临床达到预期目标, objectType=article, longId=5403, objectId=0c8c5403a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c8c5403a3, replyNumber=0, likeNumber=75, createdTime=2012-04-18, rootId=0, userName=snowpeakxu, userId=1f4f8326724, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c8c5403a3, moduleTitle=礼来（Lilly）公司牛皮癣单抗药物ixekizumab中期临床达到预期目标, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0c8c5403a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ixekizumab

2020-05-29

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

ARD：ixekizumab 在银屑病关节炎患者中的安全性：来自超过2000患者年暴露的四项临床试验的数据

2022-07-05

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

JEADV:Suckinumab与Ixekizumab治疗脓疱型和红皮病型银屑病的临床比较

2022-03-20

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

J Dermatolog Treat：ixekizumab治疗严重斑块状银屑病患者的疗效和安全性

2022-02-22

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

JEADV:Risankizumab和Ixekizumab治疗生殖器银屑病的比较

2021-12-29

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

Br J Dermatol：ixekizumab与guselkumab治疗中重度斑块状银屑病的疗效和安全性

2021-12-19

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

JEADV:Ixekizumab可中到重度生殖器银屑病相关的性影响

2021-12-03

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

ARD:评估Taltz(ixekizumab)与阿达木单抗治疗银屑病关节炎患者的疗效和安全性

2021-09-09

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

JAAD:Ixekizumab 的长期疗效和安全性

2021-09-08

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

如何治疗继发于阿达木单抗功效丧失的化脓性汗腺炎？可选择Ixekizumab

2020-11-10

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

Lancet：Ixekizumab 治疗非放射学轴向脊椎关节炎

2019-12-11

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

Ann Rheum Dis：两项使用ixekizumab治疗活动性放射学axSpA 3期临床试验的疗效和安全性（COAST-V和COAST-W）

2019-11-23

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

2019年ACR / ARP：COAST-X研究展示了ixekizumab治疗非放射性轴性脊柱关节炎的积极数据

2019-11-15

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

Arthritis Rheumatol：ixekizumab对放射性轴性脊柱关节炎的疗效和安全性

2018-10-28

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

Lancet:IL-17A单抗ixekizumab可有效改善X线轴向骨关节炎患者症状

2018-10-25

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

Br J Dermatol：Ixekizumab治疗银屑病起效迅速且疗效较优

2017-10-30

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

NEJM：新药物ixekizumab可根治牛皮癣

2016-06-15

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

The Lancet：单抗药物ixekizumab中和白介素IL-17A 成功治疗银屑病

2015-06-14

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

Lancet：治疗中度至重度银屑病，ixekizumab优于依那西普

2015-06-13

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

礼来IL-17A单抗ixekizumab银屑病关节炎III期成功

2015-04-24

snowpeakxu (审核中...)

前往app查看评论内容

#ixekizumab#

礼来（Lilly）公司牛皮癣单抗药物ixekizumab中期临床达到预期目标

2012-04-18

科室
- - 订阅+
  - 更多科室
工具
服务